{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:02:06Z","timestamp":1789610526162,"version":"build-2803163510"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic hepatitis B (CHB) affects nearly 300\u00a0million people worldwide and is a leading cause of hepatocellular carcinoma (HCC). While cirrhosis is a risk factor for HCC, hepatitis B virus (HBV) DNA integration can lead to HCC in non-cirrhotic individuals. This study synthesized existing data to compare HCC risk among non-cirrhotic patients treated with antivirals versus those untreated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic literature review was conducted. Databases were searched in February 2023 and handsearches were performed to identify studies reporting HCC incidence in non-cirrhotic CHB patients, both treated with antivirals for a mean or median duration of at least three years and untreated. A meta-analysis compared HCC incidence rates between treated and untreated populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Two thousand, one hundred sixty-four records were screened and 61 publications on 50 studies were included. HCC cumulative incidence rates increased with greater follow-up, ranging from 0 to 3% at one year and 0 to 30% at 10 years. Incidence rates ranged from 0 per 100 to 2.43 per 100 person-years. The comparative meta-analysis of four studies indicated that treated populations had a 40% reduction in HCC incidence compared to untreated groups (incidence rate ratio [IRR]: 0.59; 95% CI: 0.50, 0.69), with incidence rates expressed per 100 person-years. Sensitivity analyses confirmed the robustness of these findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Antiviral therapy significantly reduces HCC risk in non-cirrhotic CHB patients. These results, with other literature, support treatment guideline expansion to include non-cirrhotic individuals and prevent HCC development. Further research is necessary to evaluate the impact of early versus late treatment initiation and explore potential differences between antivirals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>PROSPERO ID: CRD42023396260. Date of registration: 11 April 2023.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-026-04996-y","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T09:44:41Z","timestamp":1782467081000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hepatocellular carcinoma risk reduction associated with antiviral treatment in patients with noncirrhotic chronic hepatitis B: a systematic literature review and comparative meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Arpan","family":"Mohanty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice E.","family":"Stead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"Telep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda W.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Curteis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Zolotor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Frenette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dona","family":"Khoshabafard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"McQuaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin K.","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"4996_CR1","unstructured":"WHO. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. World Health Organization; 2024. 29 March 2024."},{"key":"4996_CR2","doi-asserted-by":"crossref","unstructured":"Cornberg M, Sandmann L, Jaroszewicz J, Kennedy P, Lampertico P, Lemoine M, et al. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2025;67(2):370\u201398.","DOI":"10.1016\/j.jhep.2025.03.018"},{"key":"4996_CR3","unstructured":"WHO, Hepatitis B, World Health Organization. 2022. updated 24 June 2022. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b"},{"issue":"12","key":"4996_CR4","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1002\/ijc.31280","volume":"142","author":"D Maucort-Boulch","year":"2018","unstructured":"Maucort-Boulch D, de Martel C, Franceschi S, Plummer M. Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide. Int J Cancer. 2018;142(12):2471\u20137.","journal-title":"Int J Cancer"},{"key":"4996_CR5","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.2147\/JHC.S544589","volume":"12","author":"QB Wang","year":"2025","unstructured":"Wang QB, Luo WL, Li YK, Li J, Yang ZS, Zhao K, et al. Tumor Compression of the Hepatic or Portal Vein Predicts the Presence of Microvascular Invasion and Satellite Nodules in Hepatocellular Carcinoma: A Retrospective Study. J Hepatocell Carcinoma. 2025;12:2055\u201367.","journal-title":"J Hepatocell Carcinoma"},{"issue":"3","key":"4996_CR6","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1002\/cam4.1998","volume":"8","author":"K Tarao","year":"2019","unstructured":"Tarao K, Nozaki A, Ikeda T, Sato A, Komatsu H, Komatsu T, et al. Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases\u2014meta-analytic assessment. Cancer Med. 2019;8(3):1054\u201365.","journal-title":"Cancer Med"},{"issue":"1","key":"4996_CR7","doi-asserted-by":"publisher","first-page":"e16202","DOI":"10.1111\/liv.16202","volume":"45","author":"T Tu","year":"2025","unstructured":"Tu T, McQuaid TJ, Jacobson IM, HBV-Induced Carcinogenesis. Mechanisms, Correlation With Viral Suppression, and Implications for Treatment. Liver Int. 2025;45(1):e16202.","journal-title":"Liver Int"},{"key":"4996_CR8","unstructured":"IARC. IARC Monographs on the Identification of Carcinogenic Hazards to Humans. IARC; Updated February 14, 2025. Available from: https:\/\/monographs.iarc.who.int\/list-of-classifications\/."},{"key":"4996_CR9","doi-asserted-by":"crossref","unstructured":"Basu AK. DNA Damage, Mutagenesis and Cancer. Int J Mol Sci. 2018;19(4):970.","DOI":"10.3390\/ijms19040970"},{"issue":"1","key":"4996_CR10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s40364-024-00611-y","volume":"12","author":"M Zhang","year":"2024","unstructured":"Zhang M, Chen H, Liu H, Tang H. The impact of integrated hepatitis B virus DNA on oncogenesis and antiviral therapy. Biomark Res. 2024;12(1):84.","journal-title":"Biomark Res"},{"issue":"3","key":"4996_CR11","doi-asserted-by":"publisher","first-page":"e801","DOI":"10.1093\/cid\/ciac383","volume":"76","author":"N Chow","year":"2023","unstructured":"Chow N, Wong D, Lai CL, Mak LY, Fung J, Ma HT, et al. Effect of Antiviral Treatment on Hepatitis B Virus Integration and Hepatocyte Clonal Expansion. Clin Infect Dis. 2023;76(3):e801\u20139.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"4996_CR12","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.jhep.2015.01.002","volume":"62","author":"GV Papatheodoridis","year":"2015","unstructured":"Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol. 2015;62(4):956\u201367.","journal-title":"J Hepatol"},{"key":"4996_CR13","doi-asserted-by":"publisher","first-page":"104783","DOI":"10.1016\/j.antiviral.2020.104783","volume":"177","author":"A Koffas","year":"2020","unstructured":"Koffas A, Petersen J, Kennedy PT. Reasons to consider early treatment in chronic hepatitis B patients. Antiviral Res. 2020;177:104783.","journal-title":"Antiviral Res"},{"issue":"4","key":"4996_CR14","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560\u201399.","journal-title":"Hepatology"},{"issue":"1","key":"4996_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1\u201398.","journal-title":"Hepatol Int"},{"key":"4996_CR16","volume-title":"Systematic Reviews: CRD\u2019s guidance for undertaking reviews in health care","author":"Centre for Reviews and Dissemination","year":"2008","unstructured":"Centre for Reviews and Dissemination. Systematic Reviews: CRD\u2019s guidance for undertaking reviews in health care. York: Centre for Reviews and Dissemination, University of York; 2008."},{"key":"4996_CR17","doi-asserted-by":"crossref","unstructured":"Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Chapter 5: Systematic Reviews of Prevalence and Incidence. 2020.","DOI":"10.46658\/JBIRM-17-05"},{"issue":"4","key":"4996_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153\u201360.","journal-title":"Evid Based Ment Health"},{"key":"4996_CR19","unstructured":"Team D. R: A Language and Environment for Statistical ComputingTeam RDCVienna, Austria2006. 12013."},{"issue":"1","key":"4996_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2307\/2530643","volume":"41","author":"S Greenland","year":"1985","unstructured":"Greenland S, Robins JM. Estimation of a common effect parameter from sparse follow-up data. Biometrics. 1985;41(1):55\u201368.","journal-title":"Biometrics"},{"issue":"18","key":"4996_CR21","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1002\/sim.1221","volume":"21","author":"B Baujat","year":"2002","unstructured":"Baujat B, Mah\u00e9 C, Pignon JP, Hill C. A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials. Stat Med. 2002;21(18):2641\u201352.","journal-title":"Stat Med"},{"issue":"3","key":"4996_CR22","doi-asserted-by":"publisher","first-page":"E240","DOI":"10.1111\/hepr.12976","volume":"48","author":"Y Ando","year":"2018","unstructured":"Ando Y, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Hayashi K, et al. Cumulative incidence and risk factors for the development of hepatocellular carcinoma in patients with chronic hepatitis B who achieved sustained disappearance of viremia by nucleos(t)ide analog treatment. Hepatol Res. 2018;48(3):E240\u201351.","journal-title":"Hepatol Res"},{"key":"4996_CR23","doi-asserted-by":"crossref","unstructured":"Chiu SM, Kuo YH, Wang JH, Hung CH, Hu TH, Lu SN, et al. Associations of HBV Genotype B vs C Infection With Relapse After Cessation of Entecavir or Tenofovir therapy. Clin Gastroenterol hepatology: official Clin Pract J Am Gastroenterological Association. 2020;18(13):2989\u201397.e3.","DOI":"10.1016\/j.cgh.2020.04.048"},{"issue":"12","key":"4996_CR24","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1136\/gutjnl-2013-306409","volume":"63","author":"JY Cho","year":"2014","unstructured":"Cho JY, Paik YH, Sohn W, Cho HC, Gwak GY, Choi MS, et al. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. Gut. 2014;63(12):1943\u201350.","journal-title":"Gut"},{"issue":"3","key":"4996_CR25","doi-asserted-by":"publisher","first-page":"406","DOI":"10.14309\/ajg.0000000000000490","volume":"115","author":"J Choi","year":"2020","unstructured":"Choi J, Kim GA, Han S, Lim YS. Earlier Alanine Aminotransferase Normalization During Antiviral Treatment Is Independently Associated With Lower Risk of Hepatocellular Carcinoma in Chronic Hepatitis B. Am J Gastroenterol. 2020;115(3):406\u201314.","journal-title":"Am J Gastroenterol"},{"key":"4996_CR26","doi-asserted-by":"crossref","unstructured":"Choi WM, Kim GA, Choi J, Han S, Lim YS. Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B. J Clin Invest. 2022;132(10):e154833.","DOI":"10.1172\/JCI154833"},{"key":"4996_CR27","first-page":"S305","volume":"76","author":"WM Choi","year":"2022","unstructured":"Choi WM, Yip TCF, Wong GLH, Yee LJ, Curteis T, Clark LJ, et al. Baseline Viral Load Is Associated with the on-Treatment Risk of Hepatocellular Carcinoma in Non-Cirrhotic, Hbeag-Positive Chronic Hepatitis B Patients: Results from an Individual Patient Data Meta-Analysis from Three Countries. Hepatology. 2022;76:S305\u20136.","journal-title":"Hepatology"},{"key":"4996_CR28","doi-asserted-by":"crossref","unstructured":"Chun HS, Park S, Lee M, Cho Y, Kim HS, Choe AR, et al. Association of physical activity with the risk of hepatocellular carcinoma in patients with chronic hepatitis b. Cancers. 2021;13(14):3424.","DOI":"10.3390\/cancers13143424"},{"issue":"12","key":"4996_CR29","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1111\/liv.15019","volume":"41","author":"LNC Dezanet","year":"2021","unstructured":"Dezanet LNC, Miailhes P, Lascoux-Combe C, Chas J, Maylin S, Gabassi A, et al. Profiles of liver fibrosis evolution during long-term tenofovir treatment in HIV-positive patients coinfected with hepatitis B. Liver Int. 2021;41(12):2874\u201384.","journal-title":"Liver Int"},{"issue":"2","key":"4996_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1872-034X.2009.00582.x","volume":"40","author":"T Hosaka","year":"2010","unstructured":"Hosaka T, Suzuki F, Kobayashi M, Hirakawa M, Kawamura Y, Yastuji H, et al. Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants. Hepatol Res. 2010;40(2):145\u201352.","journal-title":"Hepatol Res"},{"issue":"1","key":"4996_CR31","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/hep.26180","volume":"58","author":"T Hosaka","year":"2013","unstructured":"Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013;58(1):98\u2013107.","journal-title":"Hepatology"},{"issue":"1","key":"4996_CR32","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/hep4.1819","volume":"6","author":"T Hosaka","year":"2022","unstructured":"Hosaka T, Suzuki F, Fujiyama S, Kawamura Y, Sezaki H, Akuta N, et al. Ultrasensitive Assay for Hepatitis B Core-Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir. Hepatol Commun. 2022;6(1):36\u201349.","journal-title":"Hepatol Commun"},{"key":"4996_CR33","doi-asserted-by":"publisher","first-page":"S377","DOI":"10.1016\/S0168-8278(22)01107-2","volume":"77","author":"D Ji","year":"2022","unstructured":"Ji D, Chen Y, Dong Z, Xiao XH, Yang Y. Incidence of hepatocellular carcinoma reduced in chronic hepatitis B patients treated with entercavir plus Biejia-Ruangan: extended follow-up of a multicenter, randomised, double-blinded, placebo-controlled trial. J Hepatol. 2022;77:S377\u20138.","journal-title":"J Hepatol"},{"issue":"20","key":"4996_CR34","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1002\/cncr.29537","volume":"121","author":"WR Kim","year":"2015","unstructured":"Kim WR, Loomba R, Berg T, Aguilar Schall RE, Yee LJ, Dinh PV, et al. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer. 2015;121(20):3631\u20138.","journal-title":"Cancer"},{"issue":"11","key":"4996_CR35","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/jvh.12723","volume":"24","author":"GA Kim","year":"2017","unstructured":"Kim GA, Han S, Kim HD, An J, Lim YS. Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response. J Viral Hepatitis. 2017;24(11):990\u20137.","journal-title":"J Viral Hepatitis"},{"issue":"2","key":"4996_CR36","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/hep.28916","volume":"66","author":"JH Kim","year":"2017","unstructured":"Kim JH, Sinn DH, Kang W, Gwak GY, Paik YH, Choi MS, et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. Hepatology. 2017;66(2):335\u201343.","journal-title":"Hepatology"},{"issue":"12","key":"4996_CR37","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1111\/jvh.12971","volume":"25","author":"BG Kim","year":"2018","unstructured":"Kim BG, Park NH, Lee SB, Lee H, Lee BU, Park JH, et al. Mortality, liver transplantation and hepatic complications in patients with treatment-naive chronic hepatitis B treated with entecavir vs tenofovir. J Viral Hepatitis. 2018;25(12):1565\u201375.","journal-title":"J Viral Hepatitis"},{"key":"4996_CR38","doi-asserted-by":"crossref","unstructured":"Ko KL, To WP, Mak LY, Seto WK, Ning Q, Fung J et al. A large real-world cohort study examining the effects of long-term entecavir on hepatocellular carcinoma and HBsAg seroclearance. J Viral Hepatitis. 2019;21.","DOI":"10.1111\/jvh.13237"},{"issue":"5","key":"4996_CR39","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1872-034X.2011.00785.x","volume":"41","author":"H Kobashi","year":"2011","unstructured":"Kobashi H, Miyake Y, Ikeda F, Yasunaka T, Nishino K, Moriya A, et al. Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine. Hepatol Res. 2011;41(5):405\u201316.","journal-title":"Hepatol Res"},{"issue":"5","key":"4996_CR40","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1111\/jgh.14454","volume":"34","author":"R Kozuka","year":"2019","unstructured":"Kozuka R, Enomoto M, Sato-Matsubara M, Yoshida K, Motoyama H, Hagihara A, et al. Association between HLA-DQA1\/DRB1 polymorphism and development of hepatocellular carcinoma during entecavir treatment. J Gastroenterol Hepatol (Australia). 2019;34(5):937\u201346.","journal-title":"J Gastroenterol Hepatol (Australia)"},{"issue":"5","key":"4996_CR41","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1053\/j.gastro.2007.08.079","volume":"133","author":"P Lampertico","year":"2007","unstructured":"Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low Resistance to Adefovir Combined With Lamivudine: A 3-Year Study of 145 Lamivudine-Resistant Hepatitis B Patients. Gastroenterology. 2007;133(5):1445\u201351.","journal-title":"Gastroenterology"},{"issue":"3","key":"4996_CR42","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3350\/cmh.2016.0021","volume":"22","author":"J Lee","year":"2016","unstructured":"Lee J, Yoo SH, Sohn W, Kim HW, Choi YS, Won JH, et al. Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B. Clin Mol Hepatol. 2016;22(3):339\u201349.","journal-title":"Clin Mol Hepatol"},{"issue":"13","key":"4996_CR43","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1016\/j.cgh.2019.01.044","volume":"17","author":"HW Lee","year":"2019","unstructured":"Lee HW, Park JY, Kim SG, Tak WY, Yim HJ, Jang BK, et al. Long-term Outcomes of Antiviral Therapy in Patients With Advanced Chronic HBV Infection. Clin Gastroenterol Hepatol. 2019;17(13):2811\u2013e31.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4996_CR44","doi-asserted-by":"crossref","unstructured":"Lee J, Kim GA, Kim HJ, Cho S, Ko MJ, Lim YS. Tenofovir Disoproxil Fumarate on the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Failure to Preceding Treatments: A Nationwide Cohort Study. J Viral Hepatitis. 2021;28(8):1150\u20139.","DOI":"10.1111\/jvh.13530"},{"key":"4996_CR45","doi-asserted-by":"crossref","unstructured":"Lee JH, Shin SK, Kang SH, Kim TH, Yim HJ, Yim SY, et al. Long-Term Prediction Model for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Antiviral Therapy: Based on Data from Korean Patients. J Clin Med. 2022;11(22):6613.","DOI":"10.3390\/jcm11226613"},{"issue":"3","key":"4996_CR46","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.clinre.2016.11.007","volume":"41","author":"ZQ Li","year":"2017","unstructured":"Li ZQ, Hu CL, Yu P, Gu XY, Zhang JJ, Li H, et al. The development of hepatocarcinoma after long-term antivirus treatment of Chinese patients with chronic hepatitis B virus infection: Incidence, long-term outcomes and predictive factors. Clin Res Hepatol Gastroenterol. 2017;41(3):311\u20138.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"1","key":"4996_CR47","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1053\/j.gastro.2014.02.033","volume":"147","author":"YS Lim","year":"2014","unstructured":"Lim YS, Han S, Heo NY, Shim JH, Lee HC, Suh DJ. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. Gastroenterology. 2014;147(1):152\u201361.","journal-title":"Gastroenterology"},{"issue":"1","key":"4996_CR48","first-page":"E13818","volume":"98","author":"CC Lin","year":"2019","unstructured":"Lin CC, Bair MJ, Liu CY, Lin ZY, Chen CJ, Chen MJ, et al. High percentage atypical hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs. Med (United States). 2019;98(1):E13818.","journal-title":"Med (United States)"},{"issue":"3","key":"4996_CR49","doi-asserted-by":"publisher","first-page":"395","DOI":"10.5009\/gnl14170","volume":"9","author":"JC Moon","year":"2015","unstructured":"Moon JC, Kim SH, Kim IH, Lee CH, Kim SW, Lee SO, et al. Disease progression in chronic hepatitis B patients under long-term antiviral therapy. Gut Liver. 2015;9(3):395\u2013404.","journal-title":"Gut Liver"},{"key":"4996_CR50","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12876-016-0454-z","volume":"16","author":"N Nagata","year":"2016","unstructured":"Nagata N, Kagawa T, Hirose S, Arase Y, Tsuruya K, Anzai K, et al. Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B. BMC Gastroenterol. 2016;16:38.","journal-title":"BMC Gastroenterol"},{"issue":"7","key":"4996_CR51","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/jvh.12054","volume":"20","author":"GA Niro","year":"2013","unstructured":"Niro GA, Ippolito AM, Fontana R, Valvano MR, Gioffreda D, Iacobellis A, et al. Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues. J Viral Hepatitis. 2013;20(7):502\u20139.","journal-title":"J Viral Hepatitis"},{"key":"4996_CR52","doi-asserted-by":"crossref","unstructured":"Oh H, Yoon EL, Jun DW, Ahn SB, Lee HY, Jeong JY, et al. No Difference in Incidence of Hepatocellular Carcinoma in Patients With Chronic HBV Infection Treated With Entecavir vs Tenofovir. Clin Gastroenterol hepatology: official Clin Pract J Am Gastroenterological Association. 2020;18(12):2793\u2013802.","DOI":"10.1016\/j.cgh.2020.02.046"},{"issue":"8","key":"4996_CR53","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1111\/hepr.12427","volume":"45","author":"E Orito","year":"2015","unstructured":"Orito E, Hasebe C, Kurosaki M, Osaki Y, Joko K, Watanabe H, et al. Risk of hepatocellular carcinoma in cirrhotic hepatitis B virus patients during nucleoside\/nucleotide analog therapy. Hepatol Res. 2015;45(8):872\u20139.","journal-title":"Hepatol Res"},{"key":"4996_CR54","doi-asserted-by":"crossref","unstructured":"Papatheodoridis GV, Sypsa V, Dalekos GN, Yurdaydin C, Van Boemmel F, Buti M, et al. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. J Hepatol. 2020;72(6):1088\u201396.","DOI":"10.1016\/j.jhep.2020.01.007"},{"issue":"2","key":"4996_CR55","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.jhep.2014.08.045","volume":"62","author":"GV Papatheodoridis","year":"2015","unstructured":"Papatheodoridis GV, Dalekos GN, Yurdaydin C, Buti M, Goulis J, Arends P, et al. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. J Hepatol. 2015;62(2):363\u201370.","journal-title":"J Hepatol"},{"issue":"5","key":"4996_CR56","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/hep.29320","volume":"66","author":"GV Papatheodoridis","year":"2017","unstructured":"Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, van Boemmel F, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology. 2017;66(5):1444\u201353.","journal-title":"Hepatology"},{"issue":"3","key":"4996_CR57","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/liv.15128","volume":"42","author":"M Papatheodoridi","year":"2022","unstructured":"Papatheodoridi M, Su TH, Hadziyannis E, Liao CH, Orfanidou A, Yang HC, et al. Hepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicentre cohort study. Liver Int. 2022;42(3):541\u201350.","journal-title":"Liver Int"},{"issue":"2","key":"4996_CR58","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/hep.29497","volume":"68","author":"GV Papatheodoridis","year":"2018","unstructured":"Papatheodoridis GV, Manolakopoulos S, Su T-H, Siakavellas S, Liu C-J, Kourikou A, et al. Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B. Hepatology. 2018;68(2):415\u201324.","journal-title":"Hepatology"},{"issue":"4","key":"4996_CR59","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/S1665-2681(19)30844-0","volume":"13","author":"AM Pellicelli","year":"2014","unstructured":"Pellicelli AM, Vignally P, Messina V, Izzi A, Mazzoni E, Barlattani A, et al. Long term nucleotide and nucleoside analogs treatment in chronic hepatitis B HBeAg negative genotype D patients and risk for hepatocellular carcinoma. Ann Hepatol. 2014;13(4):376\u201385.","journal-title":"Ann Hepatol"},{"issue":"3","key":"4996_CR60","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","volume":"162","author":"G Hirode","year":"2022","unstructured":"Hirode G, Choi HSJ, Chen CH, Su TH, Seto WK, Van Hees S, et al. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study). Gastroenterology. 2022;162(3):757\u2013e714.","journal-title":"Gastroenterology"},{"issue":"9","key":"4996_CR61","first-page":"1029","volume":"52","author":"JJ Shim","year":"2017","unstructured":"Shim JJ, Oh CH, Kim JW, Lee CK, Kim BH. Liver cirrhosis stages and the incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral therapy. Scand J Gastroenterol. 2017;52(9):1029\u201336.","journal-title":"Scand J Gastroenterol"},{"issue":"7","key":"4996_CR62","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/s41395-018-0093-9","volume":"113","author":"JW Shin","year":"2018","unstructured":"Shin JW, Jung SW, Lee SB, Lee BU, Park BR, Park EJ, et al. Medication Nonadherence Increases Hepatocellular Carcinoma, Cirrhotic Complications, and Mortality in Chronic Hepatitis B Patients Treated With Entecavir. Am J Gastroenterol. 2018;113(7):998\u20131008.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"4996_CR63","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s12072-020-10031-3","volume":"14","author":"FM Sou","year":"2020","unstructured":"Sou FM, Hu TH, Hung CH, Lai HC, Wang JH, Lu SN, et al. Incidence and predictors of hepatocellular carcinoma beyond year 5 of entecavir therapy in chronic hepatitis B patients. Hep Intl. 2020;14(4):513\u201320.","journal-title":"Hep Intl"},{"issue":"10","key":"4996_CR64","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/ajg.2017.254","volume":"112","author":"TC Tseng","year":"2017","unstructured":"Tseng TC, Liu CJ, Su TH, Yang WT, Chen CL, Yang HC, et al. Fibrosis-4 Index Helps Identify HBV Carriers with the Lowest Risk of Hepatocellular Carcinoma. Am J Gastroenterol. 2017;112(10):1564\u201374.","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"4996_CR65","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1111\/jgh.13294","volume":"31","author":"HM Wang","year":"2016","unstructured":"Wang HM, Hung CH, Lee CM, Lu SN, Wang JH, Yen YH, et al. Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naive and nucleos(t)ide analog-experienced chronic hepatitis B patients. J Gastroenterol Hepatol. 2016;31(7):1307\u201314.","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"4996_CR66","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1053\/j.gastro.2013.02.002","volume":"144","author":"GL Wong","year":"2013","unstructured":"Wong GL, Chan HL, Chan HY, Tse PC, Tse YK, Mak CW, et al. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. Gastroenterology. 2013;144(5):933\u201344.","journal-title":"Gastroenterology"},{"issue":"7","key":"4996_CR67","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.cmi.2017.02.001","volume":"23","author":"IT Wu","year":"2017","unstructured":"Wu IT, Hu TH, Hung CH, Lu SN, Wang JH, Lee CM, et al. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study. Clin Microbiol Infect. 2017;23(7):464\u20139.","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"4996_CR68","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00535-014-1010-7","volume":"50","author":"R Yamada","year":"2015","unstructured":"Yamada R, Hiramatsu N, Oze T, Morishita N, Harada N, Yakushijin T, et al. Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection. J Gastroenterol. 2015;50(7):785\u201394.","journal-title":"J Gastroenterol"},{"issue":"9","key":"4996_CR69","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1093\/jac\/dkt147","volume":"68","author":"SC Yang","year":"2013","unstructured":"Yang SC, Lee CM, Hu TH, Wang JH, Lu SN, Hung CH, et al. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants. J Antimicrob Chemother. 2013;68(9):2154\u201363.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"4996_CR70","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s10157-013-0807-7","volume":"18","author":"YW Yang","year":"2014","unstructured":"Yang YW, Lee CY, Hu RH, Lee PH, Tsai MK. Long-term effects of prophylactic and therapeutic lamivudine treatments in hepatitis B surface antigen-positive renal allograft recipients. Clin Exp Nephrol. 2014;18(1):144\u201350.","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"4996_CR71","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/j.gastro.2019.09.025","volume":"158","author":"TC Yip","year":"2020","unstructured":"Yip TC, Wong VW, Chan HL, Tse YK, Lui GC, Wong GL. Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China. Gastroenterology. 2020;158(1):215\u201325. e6.","journal-title":"Gastroenterology"},{"issue":"8","key":"4996_CR72","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1177\/135965350701200816","volume":"12","author":"MF Yuen","year":"2007","unstructured":"Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther. 2007;12(8):1295\u2013303.","journal-title":"Antivir Ther"},{"issue":"4","key":"4996_CR73","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/jmv.20305","volume":"75","author":"N Akuta","year":"2005","unstructured":"Akuta N, Suzuki F, Suzuki Y, Sezaki H, Hosaka T, Someya T, et al. Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study. J Med Virol. 2005;75(4):491\u20138.","journal-title":"J Med Virol"},{"issue":"4","key":"4996_CR74","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1136\/gutjnl-2023-330225","volume":"73","author":"W-M Choi","year":"2024","unstructured":"Choi W-M, Kim G-A, Choi J, Choi GH, Lee YB, Sinn DH, et al. Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B. Gut. 2024;73(4):649\u201358.","journal-title":"Gut"},{"issue":"4","key":"4996_CR75","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2468-1253(24)00431-X","volume":"10","author":"YS Lim","year":"2025","unstructured":"Lim YS, Yu ML, Choi J, Chen CY, Choi WM, Kang W, et al. Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial. Lancet Gastroenterol Hepatol. 2025;10(4):295\u2013305.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"4996_CR76","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.cgh.2024.07.031","volume":"23","author":"WM Choi","year":"2025","unstructured":"Choi WM, Yip TC, Wong GL, Kim WR, Yee LJ, Brooks-Rooney C, et al. Baseline Viral Load and On-Treatment Hepatocellular Carcinoma Risk in Chronic Hepatitis B: A Multinational Cohort Study. Clin Gastroenterol Hepatol. 2025;23(2):310\u2013\u200920.e7.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"4996_CR77","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3350\/cmh.2022.0342","volume":"29","author":"CL Lin","year":"2023","unstructured":"Lin CL, Kao JH. Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection. Clin Mol Hepatol. 2023;29(3):605\u201322.","journal-title":"Clin Mol Hepatol"},{"issue":"8","key":"4996_CR78","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/apt.17654","volume":"58","author":"GC Lui","year":"2023","unstructured":"Lui GC, Hui VW, Sze SF, Wong BC, Cheung C, Lee MP, et al. Incidence of hepatocellular carcinoma and mortality in chronic viral hepatitis in an Asian population with and without HIV infection. Aliment Pharmacol Ther. 2023;58(8):814\u201323.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"4996_CR79","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.cgh.2023.09.002","volume":"22","author":"A Chau","year":"2024","unstructured":"Chau A, Yeh ML, Tsai PC, Huang DQ, Kim SE, Trinh H, et al. Sex Differences in Treatment Response to Nucleos(t)ide Therapy in Chronic Hepatitis B: A Multicenter Longitudinal Study. Clin Gastroenterol Hepatol. 2024;22(3):572\u201380. e5.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"4996_CR80","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/HEP.0000000000000752","volume":"80","author":"WM Choi","year":"2024","unstructured":"Choi WM, Yip TC, Kim WR, Yee LJ, Brooks-Rooney C, Curteis T, et al. Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-positive patients. Hepatology. 2024;80(2):428\u201339.","journal-title":"Hepatology"},{"issue":"2","key":"4996_CR81","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.cgh.2024.07.031","volume":"23","author":"WM Choi","year":"2024","unstructured":"Choi WM, Yip TC, Wong GL, Kim WR, Yee LJ, Brooks-Rooney C, et al. Baseline Viral Load and On-Treatment Hepatocellular Carcinoma Risk in Chronic Hepatitis B: A Multinational Cohort Study. Clin Gastroenterol Hepatol. 2024;23(2):310\u201320. e7.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4996_CR82","doi-asserted-by":"publisher","first-page":"S1065","DOI":"10.1016\/S0168-8278(23)03166-5","volume":"78","author":"HS Chun","year":"2023","unstructured":"Chun HS, Lee M, Lee HA, Kim J, Lee HA, Kim HY, et al. Influence of viral load and fibrotic burden on hepatocellular carcinoma risk at phase change to immune-active phase in chronic hepatitis B. J Hepatol. 2023;78:S1065\u20136.","journal-title":"J Hepatol"},{"key":"4996_CR83","doi-asserted-by":"crossref","unstructured":"Chun HS, Lee M, Lee HA, Kim J, Lee HA, Kim HY, et al. Influence Of Viral Load And Fibrotic Burden On Hepatocellular Carcinoma Risk At Phase Change To Immune-Active Phase In Chronic Hepatitis B. AASLD. 2023.","DOI":"10.1016\/S0168-8278(23)03166-5"},{"issue":"1","key":"4996_CR84","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jhep.2023.09.011","volume":"80","author":"HS Chun","year":"2024","unstructured":"Chun HS, Papatheodoridis GV, Lee M, Lee HA, Kim YH, Kim SH, et al. PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B. J Hepatol. 2024;80(1):20\u201330.","journal-title":"J Hepatol"},{"key":"4996_CR85","doi-asserted-by":"crossref","unstructured":"Huang CW, Yang CT, Su PY, Chen YY, Huang SP, Yen HH. Long-Term Hepatitis B Surface Antigen Profile and Seroclearance Following Antiviral Treatment: A Single-Center, Real-World Cohort Study. Biomedicines. 2023;11(11):2966.","DOI":"10.3390\/biomedicines11112966"},{"issue":"2","key":"4996_CR86","doi-asserted-by":"publisher","first-page":"305","DOI":"10.5009\/gnl220390","volume":"18","author":"TH Kim","year":"2024","unstructured":"Kim TH, Kim JH, Yim HJ, Seo YS, Yim SY, Lee YS, et al. Noninferiority Outcomes of Besifovir Compared to Tenofovir Alafenamide in Treatment-Naive Patients with Chronic Hepatitis B. Gut Liver. 2024;18(2):305\u201315.","journal-title":"Gut Liver"},{"key":"4996_CR87","doi-asserted-by":"crossref","unstructured":"Lim Y-S, Wong GL-HC, Ahn SH, Seto W-K, Agarwal K. Impact Of Long-Term Treatment With Continuous Tenofovir Alafenamide (TAF) or After Switch From Tenofovir Disoproxil Fumarate (TDF) on Hepatocellular Carcinoma (HCC) Incidence in Patients with Chronic Hepatitis B (CHB). AASLD. 2023.","DOI":"10.1136\/gutjnl-2024-IDDF.189"},{"issue":"7","key":"4996_CR88","doi-asserted-by":"publisher","first-page":"101089","DOI":"10.1016\/j.jhepr.2024.101089","volume":"6","author":"H Shin","year":"2024","unstructured":"Shin H, Choi WM, Kim SU, Ko Y, Park Y, Park J, et al. Lack of association between early on-treatment HBeAg seroclearance and development of hepatocellular carcinoma or decompensated cirrhosis. JHEP Rep. 2024;6(7):101089.","journal-title":"JHEP Rep"},{"issue":"6","key":"4996_CR89","doi-asserted-by":"publisher","first-page":"S399","DOI":"10.1016\/S0016-5085(23)01924-8","volume":"164","author":"Z Yang","year":"2023","unstructured":"Yang Z, Cheung R, Jou JH, Lim JK, Wong R. Sa1523 ON-treatment risk of hepatocellular carcinoma does not differ by baseline hepatitis b viral load among a large cohort of predominantly non-asian patients with non-cirrhotic e antigen negative chronic hepatitis B. Gastroenterology. 2023;164(6):S399\u2013400.","journal-title":"Gastroenterology"},{"issue":"10","key":"4996_CR90","doi-asserted-by":"publisher","first-page":"100852","DOI":"10.1016\/j.jhepr.2023.100852","volume":"5","author":"Z Yang","year":"2023","unstructured":"Yang Z, Cheung RC, Chitnis AS, Zhang W, Gish RG, Wong RJ. On-treatment risks of cirrhosis and hepatocellular carcinoma among a large cohort of predominantly non-Asian patients with non-cirrhotic chronic hepatitis B. JHEP Rep. 2023;5(10):100852.","journal-title":"JHEP Rep"},{"issue":"1","key":"4996_CR91","first-page":"47","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4(1):47\u201353.","journal-title":"J Natl Cancer Cent"},{"issue":"5 Suppl","key":"4996_CR92","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1002\/hep.22898","volume":"49","author":"BJ McMahon","year":"2009","unstructured":"McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49(5 Suppl):S45\u201355.","journal-title":"Hepatology"},{"key":"4996_CR93","unstructured":"Singal AK, Salameh H, Fau - Kuo YF, Kuo Yf Fau - Fontana RJ, Fontana RJ. Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. (1365\u20132036 (Electronic))."},{"key":"4996_CR94","doi-asserted-by":"crossref","unstructured":"Sung JJ, Tsoi Kk Fau -, Wong VWS, Wong Vw Fau - Li KCT, Li Kc Fau - Chan HLY, Chan HL. Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. 2008(1365\u20132036 (Electronic)).","DOI":"10.1016\/S0168-8278(08)60411-0"},{"issue":"2","key":"4996_CR95","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1054\/drup.2001.0190","volume":"4","author":"KP Fischer","year":"2001","unstructured":"Fischer KP, Gutfreund KS, Tyrrell DL. Lamivudine resistance in hepatitis B: mechanisms and clinical implications. Drug Resist Updat. 2001;4(2):118\u201328.","journal-title":"Drug Resist Updat"},{"issue":"1","key":"4996_CR96","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"NA Terrault","year":"2016","unstructured":"Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261\u201383.","journal-title":"Hepatology"},{"issue":"36","key":"4996_CR97","doi-asserted-by":"publisher","first-page":"6025","DOI":"10.3748\/wjg.v27.i36.6025","volume":"27","author":"E Amponsah-Dacosta","year":"2021","unstructured":"Amponsah-Dacosta E. Hepatitis B virus infection and hepatocellular carcinoma in sub-Saharan Africa: Implications for elimination of viral hepatitis by 2030? World J Gastroenterol. 2021;27(36):6025\u201338.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"4996_CR98","doi-asserted-by":"publisher","first-page":"5723","DOI":"10.1038\/s41598-023-32865-1","volume":"13","author":"HM Kafeero","year":"2023","unstructured":"Kafeero HM, Ndagire D, Ocama P, Kato CD, Wampande E, Walusansa A, et al. Mapping hepatitis B virus genotypes on the African continent from 1997 to 2021: a systematic review with meta-analysis. Sci Rep. 2023;13(1):5723.","journal-title":"Sci Rep"},{"key":"4996_CR99","doi-asserted-by":"publisher","first-page":"299","DOI":"10.4236\/ojgas.2023.1310027","volume":"13","author":"S Kilonzo","year":"2023","unstructured":"Kilonzo S, Nkandala I, Jaka H, Marmo L. Antiviral Therapy Eligibility and Low Treatment Coverage among Hepatitis B Virus Infected Patients in Tanzania. Open J Gastroenterol. 2023;13:299\u2013312.","journal-title":"Open J Gastroenterol"},{"issue":"12","key":"4996_CR100","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/S2468-1253(17)30295-9","volume":"2","author":"CW Spearman","year":"2017","unstructured":"Spearman CW, Afihene M, Ally R, Apica B, Awuku Y, Cunha L, et al. Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets. Lancet Gastroenterol Hepatol. 2017;2(12):900\u20139.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"27","key":"4996_CR101","doi-asserted-by":"publisher","first-page":"4252","DOI":"10.3748\/wjg.v27.i27.4252","volume":"27","author":"N Fragkou","year":"2021","unstructured":"Fragkou N, Sideras L, Panas P, Emmanouilides C, Sinakos E. Update on the association of hepatitis B with intrahepatic cholangiocarcinoma: Is there new evidence? World J Gastroenterol. 2021;27(27):4252\u201375.","journal-title":"World J Gastroenterol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04996-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04996-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04996-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:02:24Z","timestamp":1789606944000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04996-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":101,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4996"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04996-y","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"6 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AES, LET, AWS, CF, KH, DK, and TM are employees of Gilead Sciences, Inc. and may own stock in Gilead Sciences, Inc. AM is supported by the Robert A. Winn Career Development Award; has previously received a research grant from Gilead Sciences, Inc.; is a site principal investigator for clinical trials sponsored by Inventiva, Kowa, Madrigal, Novo Nordisk, Atea and Takeda; has served as an advisor to Gilead Sciences, Inc., and Novo Nordisk and is on the trial adjudications committees for Medpace and Becton Dickinson. RKK has received grants from Agios, AstraZeneca, Bayer, Bristol Myers Squibb, Compass Therapeutics, Eli Lilly, Exelixis, Genentech\/Roche, Loxo Oncology, Merck, Partner Therapeutics, QED Therapeutics, Relay Therapeutics, Servier, Taiho Pharmaceutical, and Tyra Biosciences; received consulting fees from Agios, AstraZeneca, Compass Therapeutics, GSK, Jazz Pharmaceuticals, J-Pharma, Kinnate Biopharma, Merck, Moderna, Regeneron Pharmaceuticals, and Tyra Biosciences; participated on an advisory board for Genentech\/Roche and Merck; and served as a member on the Cholangiocarcinoma Foundation governance board. TC and AZ are employees of Costello Medical, the organization contracted to perform the research.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"575"}}